Melanoma: the development of immunoconjugates from a preclinical viewpoint.
Beaumier
P L
PL
NeoRx Corporation, Seattle, Washington.
Morgan
A C
AC
Woodhouse
C S
CS
Marchitto
K S
KS
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D015195:Drug Design; D004341:Drug Evaluation; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000276:immunology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000000981:diagnostic imaging / Q000276:immunology / Q000628:therapy; D058950:Melanoma-Specific Antigens; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000276:immunology; D011509:Proteoglycans / Q000276:immunology; D011877:Radionuclide Imaging; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D005732:Gangliosides; D007140:Immunoglobulin Fab Fragments; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D011509:Proteoglycans; C069150:melanoma-associated proteoglycan antigen, human; C049132:9-O-acetyl-GD3 ganglioside